[
  {
    "ts": null,
    "headline": "Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1",
    "summary": "The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.",
    "url": "https://finnhub.io/api/news?id=d5b31bccc3b347b5d74aa9945b3892ed57217d28f88d12a4a6dc3414ed7a4d02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735943400,
      "headline": "Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1",
      "id": 132261358,
      "image": "https://s.yimg.com/ny/api/res/1.2/WA_VfglI1cgw73biYU9_Iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/fortune_175/a4a09a2bd3f2a70d13ac3f3828106447",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.",
      "url": "https://finnhub.io/api/news?id=d5b31bccc3b347b5d74aa9945b3892ed57217d28f88d12a4a6dc3414ed7a4d02"
    }
  },
  {
    "ts": null,
    "headline": "Venture Capitalist Sues Paypal Over Funding Program for Minority Startups",
    "summary": "An Asian American fund manager accused the payments company of discrimination by ignoring her application under a $100 million initiative.",
    "url": "https://finnhub.io/api/news?id=f5ab4d1114cc1d2bab48928c3e66361c0808b981f097527a0c1c7c1f5dde53d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735931880,
      "headline": "Venture Capitalist Sues Paypal Over Funding Program for Minority Startups",
      "id": 132259504,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "An Asian American fund manager accused the payments company of discrimination by ignoring her application under a $100 million initiative.",
      "url": "https://finnhub.io/api/news?id=f5ab4d1114cc1d2bab48928c3e66361c0808b981f097527a0c1c7c1f5dde53d9"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Friday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=e0b16e8984a160857c344ae062505d69d34bcf23b643226ec926d2eaf71dbdce",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735922340,
      "headline": "Pfizer Inc. stock underperforms Friday when compared to competitors",
      "id": 132323917,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=e0b16e8984a160857c344ae062505d69d34bcf23b643226ec926d2eaf71dbdce"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Rises 5.6% in a Month: How Should You Play the Stock?",
    "summary": "Investors may stay invested in PFE stock to see how its new growth drivers perform",
    "url": "https://finnhub.io/api/news?id=1d408fb6d19a7c205263f896c82d87988a5f3095f62ec0f35246602caa823d30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735912380,
      "headline": "Pfizer Rises 5.6% in a Month: How Should You Play the Stock?",
      "id": 132254360,
      "image": "https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors may stay invested in PFE stock to see how its new growth drivers perform",
      "url": "https://finnhub.io/api/news?id=1d408fb6d19a7c205263f896c82d87988a5f3095f62ec0f35246602caa823d30"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More",
    "summary": "PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.",
    "url": "https://finnhub.io/api/news?id=92e94238f2c7fbba88c5a10ba0e5f17a2b7c13849bc4edf3da2c37e1588b150d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735911960,
      "headline": "Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More",
      "id": 132254361,
      "image": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.",
      "url": "https://finnhub.io/api/news?id=92e94238f2c7fbba88c5a10ba0e5f17a2b7c13849bc4edf3da2c37e1588b150d"
    }
  },
  {
    "ts": null,
    "headline": "Here’s Why Pfizer Inc. (PFE) Is Among The Stocks Targeted By Activist Hedge Funds",
    "summary": "We recently compiled a list of the 15 Stocks Targeted By Activist Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks targeted by activist hedge funds. Shareholder activism continued at a record pace in 2024 as activist hedge funds pushed for strategic changes […]",
    "url": "https://finnhub.io/api/news?id=a439af4db370f495f69481a176744b0f08db757d3f144781bf08a0071cbe036f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735906407,
      "headline": "Here’s Why Pfizer Inc. (PFE) Is Among The Stocks Targeted By Activist Hedge Funds",
      "id": 132251970,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 15 Stocks Targeted By Activist Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks targeted by activist hedge funds. Shareholder activism continued at a record pace in 2024 as activist hedge funds pushed for strategic changes […]",
      "url": "https://finnhub.io/api/news?id=a439af4db370f495f69481a176744b0f08db757d3f144781bf08a0071cbe036f"
    }
  },
  {
    "ts": null,
    "headline": "3 Ultra-High-Yield Dividend Stocks That Are Screaming Buys in 2025",
    "summary": "Three high-octane income stocks -- sporting an average yield of 7.93% -- can fatten investors' pocketbooks in the new year.",
    "url": "https://finnhub.io/api/news?id=b601e90823fc57aae5550557210eaa7f6f695057cfece3a3beac72b25cd6f6d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735899660,
      "headline": "3 Ultra-High-Yield Dividend Stocks That Are Screaming Buys in 2025",
      "id": 132251971,
      "image": "https://g.foolcdn.com/editorial/images/802551/exchange-money-dividend-payout-yield-income-stocks-invest-getty.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Three high-octane income stocks -- sporting an average yield of 7.93% -- can fatten investors' pocketbooks in the new year.",
      "url": "https://finnhub.io/api/news?id=b601e90823fc57aae5550557210eaa7f6f695057cfece3a3beac72b25cd6f6d6"
    }
  },
  {
    "ts": null,
    "headline": "10 Magnificent Stocks That Can Make You Richer in 2025",
    "summary": "A new year brings with it new opportunities to grow your wealth on Wall Street.",
    "url": "https://finnhub.io/api/news?id=5e97ece31e39a756a955604a463c7016c3c4af914860853018e81281c2b4ea4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735898760,
      "headline": "10 Magnificent Stocks That Can Make You Richer in 2025",
      "id": 132250266,
      "image": "https://g.foolcdn.com/editorial/images/802473/stopwatch-second-hand-time-to-buy-invest-stock-market-getty.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A new year brings with it new opportunities to grow your wealth on Wall Street.",
      "url": "https://finnhub.io/api/news?id=5e97ece31e39a756a955604a463c7016c3c4af914860853018e81281c2b4ea4d"
    }
  },
  {
    "ts": null,
    "headline": "Update: Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025",
    "summary": "(Updates with response from Bristol-Myers Squibb in the fourth and fifth paragraphs. Drugmakers",
    "url": "https://finnhub.io/api/news?id=4fe7bca60bb8f02ab5d32e16cdea9871adc489b2e437f2abed9654aa23592a64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735895874,
      "headline": "Update: Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025",
      "id": 132251974,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Updates with response from Bristol-Myers Squibb in the fourth and fifth paragraphs. Drugmakers",
      "url": "https://finnhub.io/api/news?id=4fe7bca60bb8f02ab5d32e16cdea9871adc489b2e437f2abed9654aa23592a64"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer",
    "summary": "Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=19a8f5d3363fd6f907ef59b816f30cbc03162df4407ca23c13c9dd0cb1d9b032",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735890300,
      "headline": "The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer",
      "id": 132249155,
      "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=19a8f5d3363fd6f907ef59b816f30cbc03162df4407ca23c13c9dd0cb1d9b032"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Berkshire Hathaway, The Home Depot, Pfizer and AMREP",
    "summary": "Berkshire Hathaway, The Home Depot, Pfizer and AMREP are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=490b79ed16b191957297b473bd9783605bada76fd17aff3a88372d1c8d494405",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735889580,
      "headline": "The Zacks Analyst Blog Berkshire Hathaway, The Home Depot, Pfizer and AMREP",
      "id": 132249109,
      "image": "https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Berkshire Hathaway, The Home Depot, Pfizer and AMREP are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=490b79ed16b191957297b473bd9783605bada76fd17aff3a88372d1c8d494405"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: A Step-By-Step Strategy Before Earnings",
    "summary": "PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth potential. See why PFE stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=dc751b80c22b375da4f4a0fe84a3ada43681b17d0e0bdc626fbbd731fdc75ce5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735884000,
      "headline": "Pfizer: A Step-By-Step Strategy Before Earnings",
      "id": 132250760,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491484031/image_1491484031.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth potential. See why PFE stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=dc751b80c22b375da4f4a0fe84a3ada43681b17d0e0bdc626fbbd731fdc75ce5"
    }
  }
]